GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TransMedics Group Inc (STU:TMDX) » Definitions » Research & Development

TransMedics Group (STU:TMDX) Research & Development : €63.9 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is TransMedics Group Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. TransMedics Group's Research & Development for the three months ended in Mar. 2024 was €10.5 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €63.9 Mil.

TransMedics Group Research & Development Historical Data

The historical data trend for TransMedics Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TransMedics Group Research & Development Chart

TransMedics Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial 17.88 15.48 19.74 25.31 58.02

TransMedics Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.48 7.65 35.93 9.87 10.47

TransMedics Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €63.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransMedics Group  (STU:TMDX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

TransMedics Group Research & Development Related Terms

Thank you for viewing the detailed overview of TransMedics Group's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

TransMedics Group (STU:TMDX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TransMedics Group Inc (STU:TMDX) » Definitions » Research & Development
Comparable Companies
ATEC UFPT PRCT TNDM SSII AHCO NVCR AVNS ESTA INMD ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
TMDX:USA 8T8:Germany
Address
200 Minuteman Road, Andover, MA, USA, 01810
Website
https://www.transmedics.com
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body.